Actuate Therapeutics Inc (ACTU-Q) Analyst Research & Price Targets - The Globe and Mail

Earnings Estimates

	Current Qtr12/2025	Next Qtr03/2026	Fiscal Yr12/2025	Fiscal Yr12/2026
Average Estimate	-0.24	-0.23	-1.06	-0.99
Number of Estimates	2	1	2	2
High Estimate	-0.24	-0.23	-1.00	-0.97
Low Estimate	-0.24	-0.23	-1.11	-1.00
Prior Year	N/A	-0.32	-3.26	-1.06
Growth Rate Est. (year over year)	-100.02%	+28.13%	+67.48%	+6.60%

Earnings History - Surprises*

	Qtr Ending09/2025	Qtr Ending06/2025	Qtr Ending03/2025	Qtr Ending12/2024
Reported	$-0.25	$-0.30	$-0.32	N/A
Estimate	$-0.27	$-0.19	$-0.26	N/A
Difference	+0.02	-0.11	-0.06	N/A
Surprise	+7.41%	-57.89%	-23.08%	N/A

* Earnings are based on GAAP income from continuing operations.

Average Analyst Ratings

4.60

3 Mths Ago5

4.60

2 Mths Ago5

4.60

1 Mth Ago5

4.60

Current5

Ratings Values:

Strong Buy5

Moderate Buy4

Hold3

Moderate Sell2

Strong Sell1

Ratings Breakdown

	3 Mths Ago	2 Mths Ago	1 Mth Ago	Current
# of Analysts:	5	5	5	5
	4	4	4	4
Holds	1	1	1	1

Key:

Strong Buy

Moderate Buy

Hold

Moderate Sell

Strong Sell

More from The Globe

The time may be right to focus on neglected stocks

Robert Tattersall

Small caps to watch: Dynacor Group, Spectral Medical, Pizza Pizza and more

Bullish on NextEra Energy Inc.

number cruncher

Ten transportation stocks to watch as oil prices rise

The most oversold and overbought stocks on the TSX

Monday’s analyst upgrades and downgrades

Insider Report: Chair sells $5-million from this stock yielding 5.8% that’s doubled in under a year

Canaccord reworks U.S. leadership in wake of regulatory settlement